Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Bringing Medicines to Market Faster Through Analytics & Machine Learning

Traditional medicine isn’t generally taken very seriously in the United States. However, Dr. Andrea Small-Howard, President and CSO at GB Sciences explained that “65% of the world still use traditional medicine either as their sole medicine or in conjunction with Western medicine.” Depending on the source, traditional plant-based medicine dates back as far as…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from I Don't Care on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Traditional medicine isn’t generally taken very seriously in the United States. However, Dr. Andrea Small-Howard, President and CSO at GB Sciences explained that “65% of the world still use traditional medicine either as their sole medicine or in conjunction with Western medicine.” Depending on the source, traditional plant-based medicine dates back as far as 60,000 years whereas Western medicine is a mere 3,000 years old.

Kevin Stevenson, I Don’t Care podcast host, sat down with the distinguished Dr. Small-Howard to discuss her work in the plant-based medicine industry. Dr. Small-Howard will also discuss the digital transformation curve with GB Sciences AI-based drug discovery platform PhAROS. This podcast is of great interest due in part to Dr. Small-Howard’s extensive resume. In fact, it is so extensive that the following introduction from her LinkedIn profile barely highlights her expertise.

“Dr. Andrea Small-Howard has 25 years of scientific research and executive experience in the biopharma industry supervising research & development, manufacturing, and quality control divisions in the US and China. Dr. Small-Howard has taken novel biological products from ideation through commercialization. She has been named an inventor on seventy+ patent applications, taken the lead in obtaining regulatory approvals from the U.S. Food and Drug Administration (‘US FDA’), and orchestrated commercial licensing deals.”

Listeners might think that they would not be able to understand or relate to such a well-educated scientific mind, but nothing could be further from the truth. Dr. Small-Howard is an engaging speaker filled with enthusiasm for her chosen line of work and her mission to normalize plant-based medicine in the United States.

“My background is in biochemistry, so I sort of see the world through a different lens and I’ve always been obsessed with the power of plant-based medicines. Traditional medicine is often overlooked as being a really powerful force here in the United States,” said Dr. Small-Howard. The doctor joined GB Sciences in 2014 to take plant-based medicine to the next level by utilizing science to maximize the potential of the cannabis plant.

More Like This Story:

Behavioral Health Is Stepping Out of the Shadows of Healthcare

Tearing Down the Barrier of Prior Authorization Through Automation

I Don't Care

Part of this channel

I Don't Care

Candid healthcare leadership conversations with Kevin Stevenson

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Rasonque’s 13.2-month survival result is about to hit hospital formularies

Rasonque’s 13.2-month survival result is about to hit hospital formularies

FDA has cleared Revolution Medicines' drug Rasonque for treating metastatic pancreatic adenocarcinoma. Hospitals are now integrating this drug into their formularies, focusing on operations like pathways, genotyping, and specialty pharmacy flow.

  • 01Rasonque has received FDA clearance for treating metastatic pancreatic adenocarcinoma.
  • 02Hospitals are working on integrating Rasonque into their formularies.
  • 03Operational focus includes pathways, genotyping, and specialty pharmacy flow.

Aug 30, 2026

Real-time radiation dose tracking is moving from badges to live dashboards in procedure rooms

Real-time radiation dose tracking is moving from badges to live dashboards in procedure rooms

Radiation Detection Company has introduced a live radiation dose tracking system called Radiant that updates every 0.2 seconds. GE HealthCare has developed browser-based imaging access for hospitals, transforming how radiation monitoring is managed in procedure rooms. This advancement in live dashboards is enhancing real-time monitoring capabilities in healthcare facilities.

  • 01Radiation Detection Company's Radiant updates radiation dose data every 0.2 seconds.
  • 02GE HealthCare has developed browser-based imaging access for better hospital management.
  • 03Live dashboards are transforming radiation monitoring in procedure rooms.

Aug 30, 2026

Microsoft’s 60% Dragon Copilot discount forces a new way to measure digital health ROI

Microsoft’s 60% Dragon Copilot discount forces a new way to measure digital health ROI

Microsoft has introduced a 60% discount for its Dragon Copilot, prompting a reevaluation of how digital health ROI is measured. The initiative targets rural hospitals, while European efforts like EDiHTA highlight the need for a consistent method to price technology evidence. This shift reflects a broader trend in healthcare towards data-driven decision-making and cost assessment.

  • 01Microsoft offers a 60% discount for Dragon Copilot aimed at rural hospitals.
  • 02There's a growing need for a standardized approach to pricing technology evidence in healthcare.
  • 03The European EDiHTA initiative exemplifies the trend of data-driven evaluation in digital health.

Aug 30, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512